Yarrow Bioscience Inc (YARW) Income Statement
YARW 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsYARW revenue and net income
Where YARW's revenue goes
2025Each bar shows an amount and its share of revenue. YARW kept −4,646.1% of revenue as net income.
YARW profit margins
YARW growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +13.8% | +6.1% | −51.4% | — |
| Gross profit | +9.2% | +4.7% | −51.1% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
YARW quarterly EPS vs estimates
Next report: November 5, 2026.
YARW income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $570,000 | $501,000 | $424,000 | $477,000 | $931,000 | $21.0M | $443,000 | $10.6M | $4.6M | $674,000 |
| Cost of revenue | $23,000 | $0 | $0 | $0 | $0 | $1.4M | $350,000 | $0 | $0 | $0 |
| Gross profit | $547,000 | $501,000 | $424,000 | $477,000 | $931,000 | $19.6M | $93,000 | $10.6M | $4.6M | $674,000 |
| Research & development | $19.2M | $30.9M | $16.3M | $18.4M | $19.5M | $43.5M | $53.8M | $53.0M | $29.0M | $11.3M |
| Sales, general & admin | $11.1M | $13.2M | $13.4M | $16.4M | — | — | $22.5M | $12.2M | $5.2M | $3.8M |
| Total operating expenses | $30.3M | $44.1M | $29.7M | $34.8M | $39.8M | −$232.9M | $76.2M | $65.2M | $34.2M | $15.0M |
| Operating income | −$29.7M | −$43.6M | −$29.3M | −$34.3M | −$38.9M | $252.5M | −$76.2M | −$54.5M | −$29.6M | −$14.3M |
| Interest expense | — | — | — | — | $5.6M | $4.4M | $921,000 | — | — | — |
| Income before taxes | −$26.7M | −$39.8M | −$27.9M | −$33.9M | −$43.8M | −$255.8M | −$73.7M | −$51.4M | −$29.1M | −$14.1M |
| Income taxes | $4,000 | $4,000 | — | $13,000 | $447,999 | −$258,000 | −$3.2M | — | −$8,000 | — |
| Net income | −$26.5M | −$39.8M | −$28.5M | −$23.2M | −$73.3M | −$255.6M | −$70.5M | −$51.4M | −$29.1M | −$14.1M |
| EBITDA | −$26.7M | −$39.8M | −$27.9M | −$33.9M | −$38.0M | −$251.1M | −$94.1M | −$54.5M | −$29.6M | −$14.3M |
| EPS (diluted) | −$39.73 | −$46.77 | −$350.23 | −$369.34 | −$1289.99 | −$8779.02 | −$11151.13 | −$8652.01 | −$1453.44 | −$44.09 |
| Gross margin | 96.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.4% | 21.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −5,219.1% | −8,710.0% | −6,900.5% | −7,189.7% | −4,179.5% | 1,203.0% | −17,210.4% | −512.5% | −645.9% | −2,126.4% |
| Net margin | −4,646.1% | −7,950.9% | −6,710.4% | −4,865.8% | −7,876.4% | −1,217.4% | −15,906.1% | −483.5% | −634.6% | −2,087.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $97,000 | $86,000 | $130,000 | $169,000 | $69,000 | $202,000 | $84,000 | $121,000 | $198,000 | $98,000 | $76,000 | $114,000 |
| Cost of revenue | $6,000 | $6,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $91,000 | $80,000 | $130,000 | $169,000 | $69,000 | $202,000 | $84,000 | $121,000 | $198,000 | $98,000 | $76,000 | $114,000 |
| Research & development | $788,000 | $817,000 | $3.0M | $5.3M | $4.9M | $6.1M | $9.7M | $10.2M | $7.3M | $3.7M | $3.0M | $3.3M |
| Sales, general & admin | $2.4M | $3.1M | $2.4M | $2.7M | $2.7M | $3.3M | $3.2M | $3.0M | $3.3M | $3.8M | — | — |
| Total operating expenses | $3.2M | $3.9M | $5.3M | $8.0M | $7.6M | $9.4M | $12.9M | $13.2M | $10.6M | $7.5M | $6.9M | $6.3M |
| Operating income | −$3.1M | −$3.8M | −$5.2M | −$7.8M | −$7.5M | −$9.2M | −$12.8M | −$13.1M | −$10.4M | −$7.4M | −$6.8M | −$6.2M |
| Interest income | — | $117,000 | — | — | — | — | — | — | — | — | — | — |
| Income before taxes | −$2.9M | −$3.6M | −$5.0M | −$7.4M | −$5.7M | −$8.6M | −$12.0M | −$12.2M | −$9.4M | −$6.2M | −$6.2M | −$6.1M |
| Income taxes | — | — | $4,000 | — | — | — | $4,000 | — | — | — | — | — |
| Net income | −$3.0M | −$3.6M | −$4.8M | −$7.3M | −$5.8M | −$8.6M | −$12.0M | −$12.2M | −$9.4M | −$6.2M | −$6.2M | −$6.6M |
| EBITDA | −$2.9M | −$3.6M | −$5.0M | −$7.4M | −$5.7M | −$8.6M | −$12.0M | −$12.2M | −$8.4M | −$6.2M | −$6.2M | −$6.1M |
| EPS (diluted) | −$2.14 | −$4.19 | — | −$8.50 | −$6.73 | −$10.09 | −$14.11 | −$14.27 | −$11.04 | −$7.34 | −$9.96 | −$100.30 |
| Gross margin | 93.8% | 93.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −3,197.9% | −4,437.2% | −4,014.6% | −4,610.7% | −10,930.4% | −4,553.0% | −15,202.4% | −10,819.0% | −5,250.5% | −7,530.6% | −8,989.5% | −5,468.4% |
| Net margin | −3,100.0% | −4,168.6% | −3,720.8% | −4,307.7% | −8,340.6% | −4,262.9% | −14,311.9% | −10,047.1% | −4,750.5% | −6,376.5% | −8,142.1% | −5,775.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in YARW's financial statements (latest annual report filed February 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
YARW financial results
In fiscal year 2025 (ended December 31, 2025), Yarrow Bioscience reported revenue of $0.6 million, up 13.8% from the year before. It had a net loss of $26.5 million, a net profit margin of −4,646.1%. Diluted earnings per share came to −$39.73. Over five years revenue grew at an average rate of −51.4% a year.
See the YARW stock overview for the latest quote and news, or the YARW chart for price history and technical indicators.
YARW income statement FAQ
What is Yarrow Bioscience's annual revenue?
Yarrow Bioscience reported total revenue of $0.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 13.8% from $0.5 million the previous year.
Is Yarrow Bioscience profitable?
No. Yarrow Bioscience reported a net loss of $26.5 million in fiscal 2025, a net profit margin of −4,646.1%; its operating margin was −5,219.1%.
What is Yarrow Bioscience's gross margin?
Yarrow Bioscience's gross margin was 96.0% in fiscal 2025: for every $100 of revenue, Yarrow Bioscience kept $96 after the direct cost of its products and services.
How much does Yarrow Bioscience spend on research and development?
Yarrow Bioscience spent $19.2 million on research and development in fiscal 2025, 3,374.9% of revenue.
How fast is Yarrow Bioscience growing?
Revenue grew −51.4% a year on average over the last five fiscal years, from $21.0 million to $0.6 million.
What are Yarrow Bioscience's earnings per share?
Yarrow Bioscience earned $-39.73 per diluted share in fiscal 2025, compared with $-46.77 a year earlier.
When will Yarrow Bioscience report its next earnings?
Yarrow Bioscience is expected to report results for the quarter ending September 30, 2026 on November 5, 2026.
When does Yarrow Bioscience's fiscal year end?
Yarrow Bioscience's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 27, 2026.